About Issar Pharmaceuticals
Issar Pharmaceuticals is a Healthcare company based in Hyderabad (India) founded in 1995. Peptide-based therapeutics are developed for treating multiple diseases. Issar Pharmaceuticals has raised $3.83 million across 1 funding round. Its Indian entity Issar Pharmaceuticals Private Limited reported revenue of ₹8.31 Cr. Issar Pharmaceuticals offers products and services including Novoskin®, Xylentra®, IS-107, and IS-217. Its focus areas include Life Sciences, Wound Care, Drugs and Dermatology.
Company details
Issar Pharmaceuticals is a developer of peptide-based therapeutic products to treat multiple diseases. The company has developed melgain which is a topical product used for vitiligo (market phase). The other pipeline products include Xylentra, a drug for wound treatment in clinical trial phase 3 with US-FDA in the preclinical stage, IS-217 drug for solid tumors (phase I), and psoriasis (US-FDA in preclinical stage). The preclinical pipeline includes drugs in the preclinical stage for inflammatory bowel disease, sepsis rheumatoid arthritis, and atopic dermatitis.
- Headquarters Hyderabad, India
- SectorsHealthcare
- Phone•••• ••••
- Website issar.co.in
- Social LinkedIn X Facebook Instagram YouTube
- Legal Name Issar Pharmaceuticals Pvt. Ltd.
- Date of Incorporation 31 Oct, 1995
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹8.31 Cr
FY 2024
- Net Loss-₹71.5 Lakh
FY 2024
- EBITDA₹2.83 Cr
FY 2024
- Total Equity Funding$3.83M (USD)
in 1 rounds
- Latest Funding Round$3.83M (USD), Series A
Feb 2019
Associated legal entities of Issar Pharmaceuticals
Issar Pharmaceuticals is associated with 3 registered companies on The Company Check; the primary company is Issar Pharmaceuticals Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Issar Pharmaceuticals Private Limited CIN U24239TG1995PTC022131 | Converted To Llp | 31 Oct 1995 | Hyderabad, Telangana | ₹8.3 Cr | 2 | 2 | View details |
| Issar Pharmaceuticals Llp CIN ACA-4921 | Active | 07 Apr 2023 | Hyderabad, Telangana | 8 | 2 | View details | |
| Issar Remedies Private Limited CIN U24230TG2020PTC142029 | Strike Off | 22 Jul 2020 | Hyderabad, Telangana | 2 | View details |
Products & Services of Issar Pharmaceuticals
Issar Pharmaceuticals offers a comprehensive portfolio of products and services, including Novoskin®, Xylentra®, IS-107, and IS-217.
Peptide-based solution for vitiligo skin conditions.
Topical product for effective wound healing applications.
Injectable therapy targeting solid tumor treatments.
Injectable for psoriasis and related skin disorders.
Apps and channels of Issar Pharmaceuticals
its YouTube channel Issar Pharma has 20 subscribers and 5 videos.
Videos from Issar Pharmaceuticals
The most watched videos on Issar Pharmaceuticals's YouTube channel, Issar Pharma (20 subscribers). Click a video to play it here.
More on Issar Pharma.
Funding Insights of Issar Pharmaceuticals
Issar Pharmaceuticals has successfully raised a total of $3.83M through 1 strategic funding round. The most recent funding activity was a Series A round of $3.83 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.83M
- Total Rounds 1
- Last Round Series A — $3.83M
- First Round $3.83M
(Feb 2019)
All 1 funding rounds of Issar Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $3.83M | Series A | – | – | – |
Board of directors of Issar Pharmaceuticals Private Limited (Issar Pharmaceuticals)
Issar Pharmaceuticals Private Limited is the primary company behind Issar Pharmaceuticals. The boards of the 3 registered companies of Issar Pharmaceuticals currently have 3 directors; the longest-serving is Venkata Babu Ram Reddy Kethireddy, appointed in 2020. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Venkata Babu Ram Reddy Kethireddy DIN 08804521 | Director | 22 Jul 2020 | 6 yrs 3 mo | Issar Remedies Private Limited |
| Rama Krishna Reddy Isanaka DIN 01663020 | Designated Partner | 07 Apr 2023 | 3 yrs 6 mo | Issar Pharmaceuticals Llp, Issar Remedies Private Limited, Issar Pharmaceuticals Private Limited |
| Isanaka Shaalini DIN 06433299 | Designated Partner | 07 Apr 2023 | 3 yrs 6 mo | Issar Pharmaceuticals Llp, Issar Pharmaceuticals Private Limited |
People of Issar Pharmaceuticals
10 people are tracked at Issar Pharmaceuticals (10 in leadership).
| Name | Role | Group |
|---|---|---|
Sheila Isanaka | Leadership | |
Vasantha | Leadership | |
| Leadership | ||
Vijay Krishna Akepati | Leadership | |
Lakshminarayana Reddy Isanaka | Leadership | |
Rajeshwari Isanka | Leadership | |
Srinivasa Rao Ramaraju | Leadership | |
Tatavarthy Satyanarayana Murthy | Leadership | |
| Leadership | ||
Seenayya Gunda | Leadership |
Complete people profiles for Issar Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Issar Pharmaceuticals
Figures of Issar Pharmaceuticals Private Limited, the primary company behind Issar Pharmaceuticals, for FY 2024. Revenue was ₹8.31 Cr. Net loss was -₹71.5 Lakh. EBITDA was ₹2.83 Cr. Revenue has grown at a compounded annual rate of -31% over three years and +12% over five years.
- ₹8.31 CrRevenue · FY 2024
- -₹71.5 LakhNet loss
- ₹2.83 CrEBITDA
- ₹55.00 CrPaid-up capital
- 2Employees (provident fund records)
- -31%Revenue CAGR, 3 years
- +12%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Issar Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Issar Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Issar Pharmaceuticals
2 dated milestones of Issar Pharmaceuticals across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Issar Pharmaceuticals is founded.
- Funding First funding round of $3.8M.
Top companies in Dermatology
2 companies that operate in the same segment as Issar Pharmaceuticals (Dermatology) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Skincare, beauty, and wellness services provided by VLCC across multiple countries. | 1989 | Delhi, Delhi, India | ||||
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured. | 2014 | Pune, Maharashtra, India | USD 25.97 M | USD 18.15 M | 508 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Issar Pharmaceuticals
Complete news archive for Issar Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Issar Pharmaceuticals
Issar Pharmaceuticals was founded in 1995 and raised its 1st funding round 24 years after it was founded.
Issar Pharmaceuticals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Issar Pharmaceuticals is a funded company, having raised a total of $3.83M across 1 funding round to date. The company's 1st funding round was a Series A of $3.83M, raised on Feb 2019.
The primary company behind Issar Pharmaceuticals, Issar Pharmaceuticals Private Limited, reported revenue of ₹8.31 Cr for FY 2024.
Issar Pharmaceuticals is a developer of peptide-based therapeutic products to treat multiple diseases. The company has developed melgain which is a topical product used for vitiligo (market phase). The other pipeline products include Xylentra, a drug for wound treatment in clinical trial phase 3 with US-FDA in the preclinical stage, IS-217 drug for solid tumors (phase I), and psoriasis (US-FDA in preclinical stage). The preclinical pipeline includes drugs in the preclinical stage for inflammatory bowel disease, sepsis rheumatoid arthritis, and atopic dermatitis.
Issar Pharmaceuticals offers Novoskin®, Xylentra®, IS-107, and IS-217.
Issar Pharmaceuticals is associated with 3 legal entities: Issar Pharmaceuticals Private Limited, Issar Pharmaceuticals Llp, Issar Remedies Private Limited.
The legal entities of Issar Pharmaceuticals currently have 3 directors, including Rama Krishna Reddy Isanaka, Isanaka Shaalini, Venkata Babu Ram Reddy Kethireddy.